Lantus and Zejula drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Lantus (insulin glargine recombinant) and Zejula (niraparib tosylate). Common drug interactions include nausea among females.

The phase IV clinical study analyzes what interactions people have when they take Lantus and Zejula. It is created by eHealthMe based on reports of 46 people who take the same drugs from the FDA, and is updated regularly.

What is Lantus?

Lantus has active ingredients of insulin glargine recombinant. It is often used in diabetes. eHealthMe is studying from 191,782 Lantus users. Check the latest studies of Lantus.

What is Zejula?

Zejula has active ingredients of niraparib tosylate. eHealthMe is studying from 22,014 Zejula users. Check the latest studies of Zejula.

On Jul, 12, 2026

46 people who take Lantus and Zejula together, and have interactions are studied.

What are the common drug interactions of Lantus and Zejula, by gender? *:

female:

Nausea (feeling of having an urge to vomit)
Vomiting
Abdominal pain
Somnolence (a state of near-sleep, a strong desire for sleep)
Blood glucose increased
Blood magnesium decreased
Urinary tract infection
Glycosylated haemoglobin increased
Haematotoxicity (toxins that destroy red blood cells)
Neutrophil count decreased (less than normal number of neutrophil a type of blood cell)

male:

n/a

What are the common drug interactions of Lantus and Zejula, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

Fatigue (feeling of tiredness)
Nausea (feeling of having an urge to vomit)
Platelet count decreased
Asthma
Hypotension (abnormally low blood pressure)
Mean cell haemoglobin decreased (less than normal haemoglobin per red blood cell in a sample of blood)
Pneumonia
Red cell distribution width increased
Urinary tract infection
Weight decreased

50-59:

Adrenocortical insufficiency acute (suddenly adrenal glands do not produce adequate amounts of steroid hormones)
Brain oedema (excess accumulation of fluid in the intracellular or extracellular spaces of the brain)
Central nervous system necrosis (destruction of central nervous system)
Cerebral haemorrhage (bleeding within the brain)
Decreased appetite
Deep vein thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis)
Dyspnoea (difficult or laboured respiration)
Emotional distress
Fluid overload (too much fluid in the blood)
Hypertension (high blood pressure)

60+:

Insomnia (sleeplessness)
Nausea (feeling of having an urge to vomit)
Neutrophil count decreased (less than normal number of neutrophil a type of blood cell)
Sinusitis (inflammation of sinus)
Blood glucose increased
Blood magnesium decreased
Blood pressure increased
Diverticulitis (digestive disease which involves the formation of pouches (diverticula) within the bowel wall)
Epistaxis (bleed from the nose)
Ovarian vein thrombosis (clot formation in ovary vein)

What are the existing conditions these people have? *

Ovarian Cancer (cancer of ovary): 31 people, 67.39%
Peripheral Swelling: 7 people, 15.22%
Fallopian Tube Cancer (cancer of fallopian tube): 7 people, 15.22%
Endometrial Cancer: 7 people, 15.22%
Hypersensitivity: 6 people, 13.04%
Stress And Anxiety: 4 people, 8.70%
Nausea (feeling of having an urge to vomit): 4 people, 8.70%
Urination - Painful: 3 people, 6.52%
Pain: 3 people, 6.52%
Ovarian Epithelial Cancer Recurrent (reoccurrence of cancer that begins in the cells on the surface of the ovary): 3 people, 6.52%

* Approximation only. Some reports may have incomplete information.

Do you take Lantus and Zejula?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously